SyntekaBio Balance Sheet Health

Financial Health criteria checks 4/6

SyntekaBio has a total shareholder equity of ₩31.6B and total debt of ₩6.9B, which brings its debt-to-equity ratio to 21.8%. Its total assets and total liabilities are ₩53.0B and ₩21.4B respectively.

Key information

21.8%

Debt to equity ratio

₩6.89b

Debt

Interest coverage ration/a
Cash₩19.75b
Equity₩31.63b
Total liabilities₩21.40b
Total assets₩53.03b

Recent financial health updates

Recent updates

Health Check: How Prudently Does SyntekaBio (KOSDAQ:226330) Use Debt?

Sep 06
Health Check: How Prudently Does SyntekaBio (KOSDAQ:226330) Use Debt?

Is SyntekaBio (KOSDAQ:226330) Weighed On By Its Debt Load?

Mar 05
Is SyntekaBio (KOSDAQ:226330) Weighed On By Its Debt Load?

We're Not Worried About SyntekaBio's (KOSDAQ:226330) Cash Burn

Apr 07
We're Not Worried About SyntekaBio's (KOSDAQ:226330) Cash Burn

Calculating The Intrinsic Value Of SyntekaBio, Inc. (KOSDAQ:226330)

Dec 23
Calculating The Intrinsic Value Of SyntekaBio, Inc. (KOSDAQ:226330)

Financial Position Analysis

Short Term Liabilities: A226330's short term assets (₩20.8B) exceed its short term liabilities (₩19.0B).

Long Term Liabilities: A226330's short term assets (₩20.8B) exceed its long term liabilities (₩2.4B).


Debt to Equity History and Analysis

Debt Level: A226330 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if A226330's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A226330 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: A226330 has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 22% each year.


Discover healthy companies